Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance

Oncogene volume 31, pages 2412–2422 (2012)Cite this article

Abstract

The incidence of malignant melanoma is growing rapidly worldwide and there is still no effective therapy for metastatic disease. Melanoma is the second most common cancer among young adults in the UK, where incidence rates have more than quadrupled since the 1970s. Increased expression of a number of DNA repair genes has been reported in melanoma and this likely contributes to its extreme resistance to conventional DNA-damaging chemotherapeutics. One such chemotherapeutic that is effective against a range of other cancers, but not melanoma, is cisplatin. The DNA repair proteins ERCC1 and XPF are needed to remove cisplatin-induced DNA damage and we have investigated the response of these proteins to cisplatin in melanoma. The expression of both genes is induced by cisplatin. Use of a MEK inhibitor showed that ERCC1, but not XPF induction was regulated by the mitogen-activated protein kinase (MAPK) pathway, with reduction in expression of DUSP6, the phosphatase that inactivates the extracellular signal-regulated kinase (ERK), being particularly important. DUSP6 overexpression prevented cisplatin induction of both ERCC1 and XPF, resulting in increased sensitivity to cisplatin. A novel ERCC1 mRNA was found that initiated upstream of the normal transcription initiation site, and was strongly regulated by both cisplatin and the MAPK pathway and its role in cisplatin resistance merits further study. The cisplatin induction of ERCC1 and XPF provides important insights into the resistance of melanoma to DNA-damaging chemotherapeutics, which is one of the major obstacles to melanoma treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Agar N, Young AR . (2005). Melanogenesis: a photoprotective response to DNA damage? Mutat Res 571: 121–132.

    Article  CAS  Google Scholar 

  • Andrieux LO, Fautrel A, Bessard A, Guillouzo A, Baffet G, Langouet S . (2007). GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res 67: 2114–2123.

    Article  CAS  Google Scholar 

  • Bermudez O, Pages G, Gimond C . (2010). The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol 299: C189–C202.

    Article  CAS  Google Scholar 

  • Bosl GJ, Motzer RJ . (1997). Testicular germ-cell cancer. N Engl J Med 337: 242–253.

    Article  CAS  Google Scholar 

  • Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B et al. (1993). Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55: 678–684.

    Article  CAS  Google Scholar 

  • Brozovic A, Osmak M . (2007). Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 251: 1–16.

    Article  CAS  Google Scholar 

  • Cancer Research UK. Cancer Statistics, (2011). http://info.cancerresearchuk.org/cancerstats.

  • Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, Chan KK et al. (2008). Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 29: 1742–1750.

    Article  CAS  Google Scholar 

  • Chapman PBL, Einhorn H, Meyers ML, Saxman S, Destro AN, Panageas KS et al. (1999). Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17: 2745–2751.

    Article  CAS  Google Scholar 

  • Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516.

    Article  CAS  Google Scholar 

  • Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR et al. (2009). Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 11: 720–731.

    Article  CAS  Google Scholar 

  • Ekerot M, Stavridis MP, Delavaine L, Mitchell MP, Staples C, Owens DM et al. (2008). Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter. Biochem J 412: 287–298.

    Article  CAS  Google Scholar 

  • Ferry KV, Hamilton TC, Johnson SW . (2000). Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 60: 1305–1313.

    Article  CAS  Google Scholar 

  • Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A . (2003). Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 162: 1807–1815.

    Article  CAS  Google Scholar 

  • Graham FL, van der Eb AJ . (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52: 456–467.

    Article  CAS  Google Scholar 

  • Gozdz A, Vashishta A, Kalita K, Szatmari E, Zheng JJ, Tamiya S et al. (2008). Cisplatin-mediated activation of extracellular signal-regulated kinases 1/2 (ERK1/2) by inhibition of ERK1/2 phosphatases. J Neurochem 106: 2056–2067.

    CAS  Google Scholar 

  • Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O et al. (1999). Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813–822.

    Article  CAS  Google Scholar 

  • Jansen B, Schlagbauer-Wadl H, Eichler HG, Wolff K, van Elsas A, Schrier PI et al. (1997). Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. Cancer Res 57: 362–365.

    CAS  Google Scholar 

  • Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968–972.

    Article  CAS  Google Scholar 

  • Johnson GL, Vaillancourt RR . (1994). Sequential protein kinase reactions controlling cell growth and differentiation. Curr Opin Cell Biol 6: 230–238.

    Article  CAS  Google Scholar 

  • Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, Dessen P et al. (2008). High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27: 565–573.

    Article  CAS  Google Scholar 

  • Kirschner K, Melton DW . (2010). Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 30: 3223–3232.

    CAS  Google Scholar 

  • Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM et al. (2010). Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol 79: 655–664.

    Article  CAS  Google Scholar 

  • Koberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR . (1997). DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 70: 551–555.

    Article  CAS  Google Scholar 

  • Koberle B, Masters JR, Hartley JA, Wood RD . (1999). Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 23: 273–276.

    Article  Google Scholar 

  • Kondoh K, Nishida E . (2007). Regulation of MAP kinases by MAP kinase phosphatases. Biochim Biophys Acta 1773: 1227–1237.

    Article  CAS  Google Scholar 

  • Kuraoka I, Kobertz WR, Ariza RR, Biggerstaff M, Essigmann JM, Wood RD . (2000). Repair of interstrand DNA crosslink initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem 275: 26632–26636.

    Article  CAS  Google Scholar 

  • Lebwohl D, Canetta R . (1998). Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34: 1522–1534.

    Article  CAS  Google Scholar 

  • Lee-Kwon W, Park D, Bernier M . (1998). Involvement of the Ras/extracellular signal-regulated kinase signalling pathway in the regulation of ERCC-1 mRNA levels by insulin. Biochem J 331: 591–597.

    Article  CAS  Google Scholar 

  • Livak KJ, Schmittgen TD . (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–428.

    Article  CAS  Google Scholar 

  • Martin LP, Hamilton TC, Schilder RJ . (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14: 1291–1295.

    Article  CAS  Google Scholar 

  • Mirmohammadsadegh A, Mota R, Gustrau A, Hassan M, Nambiar S, Marini A et al. (2007). ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol 127: 2207–2215.

    Article  CAS  Google Scholar 

  • Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973–937.

    Article  CAS  Google Scholar 

  • Oliveria SA, Saraiya M, Geller AC, Heneghan MK, Jorgensen C . (2006). Sun exposure and risk of melanoma. Arch Dis Child 91: 131–138.

    Article  CAS  Google Scholar 

  • Persons DL, Yazlovitskaya EM, Cui W, Pelling JC . (1999). Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 5: 1007–1014.

    CAS  Google Scholar 

  • Petit C, Sancar A . (1999). Nucleotide excision repair: from E. coli to man. Biochimie 81: 15–25.

    Article  CAS  Google Scholar 

  • Rabik CA, Dolan ME . (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9–23.

    Article  CAS  Google Scholar 

  • Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B . (2003). Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control 10: 297–305.

    Article  Google Scholar 

  • Selfridge J, Song L, Brownstein DG, Melton DW . (2010). Mice with DNA repair gene Ercc1 deficiency in a neural crest lineage are a model for late-onset Hirschsprung disease. DNA Repair 9: 653–660.

    Article  CAS  Google Scholar 

  • Shahzad MM, Lopez-Berestein G, Sood AK . (2009). Novel strategies for reversing platinum resistance. Drug Resist Updat 12: 148–152.

    Article  CAS  Google Scholar 

  • Song L, Winter AG, Selfridge J, Melton DW . (2011). A novel transcript for DNA repair gene Ercc1 in mouse skin. Transgenic Res 20: 109–122.

    Article  CAS  Google Scholar 

  • Stecca C, Gerber GB . (1998). Adaptive response to DNA-damaging agents: a review of potential mechanisms. Biochem Pharmacol 55: 941–951.

    Article  CAS  Google Scholar 

  • Tsao H, Atkins MB, Sober AJ . (2004). Management of cutaneous melanoma. N Engl J Med 351: 998–1012.

    Article  CAS  Google Scholar 

  • van Duin M, Koken MH, van den Tol J, ten Dijke P, Odijk H . (1987). Genomic characterization of the human DNA excision repair gene ERCC-1. Nucleic Acids Res 15: 9195–9213.

    Article  CAS  Google Scholar 

  • Vichai V, Kirtikara K . (2006). Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1: 1112–1116.

    Article  CAS  Google Scholar 

  • Wang X, Martindale JL, Holbrook NJ . (2000). Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275: 39435–39443.

    Article  CAS  Google Scholar 

  • Wang X, Martindale JL, Liu Y, Holbrook NJ . (1998). The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J 333: 291–300.

    Article  CAS  Google Scholar 

  • Welsh C, Day R, McGurk C, Masters JR, Wood RD, Koberle B . (2004). Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 110: 352–361.

    Article  CAS  Google Scholar 

  • Winter AG, Dorgan C, Melton DW . (2005). Expression of a splicing variant in the 5′-UTR of the human ERCC1 gene is not cancer related. Oncogene 24: 2110–2113.

    Article  CAS  Google Scholar 

  • Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME . (1995). Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326–1331.

    Article  CAS  Google Scholar 

  • Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP . (2003). Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 159: 439–452.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The cisplatin colony-forming assay was carried out by Ann-Marie Ritchie. We are grateful to Professor Toru Furukawa (Tohoku University School of Medicine, Japan), who kindly provided the DUSP6 plasmid. WL was supported by a China Scholarship Council/University of Edinburgh Scholarship. This work was supported by the Charon Fund.

Author information

Authors and Affiliations

  1. Institute of Genetics and Molecular Medicine, University of Edinburgh, MRC Human Genetics Unit, Western General Hospital, Edinburgh, UK

    W Li & D W Melton

Authors
  1. W Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D W Melton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D W Melton.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, W., Melton, D. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Oncogene 31, 2412–2422 (2012). https://doi.org/10.1038/onc.2011.426

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2011.426

Keywords

This article is cited by

Search

Advanced search

Quick links